title: [Sarcoïdosis and anti-TNF: a paradoxical class effect? Analysis of the French Pharmacovigilance system database and literature review].
abstract: OBJECTIVE
  To identify and characterize the observations of sarcoidosis occurring during anti-TNF blockade collected in the French Pharmacovigilance system database and reported in the literature.
  
  
  RESULTS
  Seven cases were reported in the French Pharmacovigilance system database and 39 cases (37 original) have been reported internationally. Monoclonal antibodies (infliximab and adalimumab) and fusion protein (etanercept) are equally involved. Sarcoidosis have been confirmed histologically and occurred predominantly in the rheumatoid arthritis (22) and spondylarthropathy (16).
  
  
  CONCLUSIONS
  The lack of protopathic bias suggests that these paradoxical sarcoidosis occurring during treatment with anti-TNF are a class-effect, as with psoriasis, uveitis, and IBD reported under similar conditions. Their pathogenesis remains unclear.
authors.affiliation: Centre Régional de Pharmacovigilance, Hôpital Central, CHU, Nancy, France.
authors.forename: Lucie
authors.initials: L
authors.lastname: Javot
authors.forename: Stéphane
authors.initials: S
authors.lastname: Tala
authors.forename: Julien
authors.initials: J
authors.lastname: Scala-Bertola
authors.forename: Nathalie
authors.initials: N
authors.lastname: Massy
authors.forename: Thierry
authors.initials: T
authors.lastname: Trenque
authors.forename: Bernadette
authors.initials: B
authors.lastname: Baldin
authors.forename: Michel
authors.initials: M
authors.lastname: Andréjak
authors.forename: Pierre
authors.initials: P
authors.lastname: Gillet
authors.forename: Nadine
authors.initials: N
authors.lastname: Petitpain
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000009:adverse effects; D015535:Arthritis, Psoriatic / Q000150:complications / Q000188:drug therapy; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D000068800:Etanercept; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D060735:Pharmacovigilance; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor; D012507:Sarcoidosis / Q000139:chemically induced* / Q000453:epidemiology; D025242:Spondylarthropathies / Q000150:complications / Q000188:drug therapy; D000079424:Tumor Necrosis Factor Inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000079424:Tumor Necrosis Factor Inhibitors; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept